8 September 2016 - ICER has posted a draft scoping document that will shape an upcoming report on abuse-deterrent opioids.

To address the ongoing national opioid epidemic, the FDA has issued guidance for drug manufacturers to develop abuse-deterrent opioid formulations to help patients manage pain while lowering the risk for opioid misuse. ICER's report will review the evidence on several new and emerging opioid re-formulations to evaluate how effectively these drugs reduce opioid misuse and its many consequences. Analyses will also be performed to provide information on the long-term value of abuse-deterrent opioids for the health system and for society.

The draft scoping document will be open to public comment for three weeks until Wednesday, September 28, 2016 at 5pm ET.

Read ICER draft scoping document